12:38 PM EDT, 05/15/2025 (MT Newswires) -- vTv Therapeutics ( VTVT ) reported Thursday screening has been reinitiated in its phase 3 trial of cadisegliatin as an adjunctive treatment of type 1 diabetes following a protocol amendment.

Continuous glucose monitors will now be provided to participants to inform the primary study endpoint, which is the number of level 2 and level 3 hypoglycemic events, the company said.

The amendment shortens trial duration to six months from 12, expediting time to topline data, the company said.

"We look forward to reporting topline Phase 3 data from CATT1 in the second half of 2026," said CEO Paul Sekhri.

The shares were up over 3% in recent trading.

Price: 21.96, Change: +0.65, Percent Change: +3.06